Literature DB >> 21801737

Clinical characteristics of primary hyperaldosteronism due to adrenal microadenoma.

Shigehiro Karashima1, Yoshiyu Takeda, Yuan Cheng, Takashi Yoneda, Masashi Demura, Mitsuhiro Kometani, Masashi Ohe, Shunsuke Mori, Kunimasa Yagi, Masakazu Yamagishi.   

Abstract

An increasing number of patients are being diagnosed with primary aldosteronism (PA) due to aldosterone-producing macroadenoma (APA). However, there are only limited data available on the clinical characteristics of PA that are associated with adrenal microadenoma. Of the 55 patients that were diagnosed with PA in our study, 22 patients showed a unilateral adrenal over-production of aldosterone. The histopathology of the surgically removed adrenal tissues led to six patients being diagnosed with microadenoma, and the clinical features of microadenoma, macroadenoma and idiopathic hyperaldosteronism (IHA) were studied. The expression levels of CYP11B2, CYP17, CYP21 and 3β-hydroxysteroid dehydrogenase 2 (HSD3B2) mRNA in the adrenal cortices (n=5 and 6, respectively) that remained attached to the adrenal microadenomas or macroadenomas were examined by real time-PCR and then compared to the expression levels in the adrenal cortices (n=5) of non-functioning adrenal adenomas (NF). The patients with microadenoma (n=6) had significantly higher diastolic blood pressure than the patients with macroadenoma (n=16) or IHA (n=33) (p<0.05). The systolic blood pressure, plasma aldosterone concentration, serum potassium level and renal function did not differ between the PA sub-groups. The levels of CYP11B2 and CYP17 mRNA were significantly increased in the adjacent tissues of microadenomas, as compared with macroadenomas or NF (p<0.05), whereas no significant differences in the CYP21 and HSD3B2 mRNA levels were found between the PA sub-groups. The tumor size did not influence the clinical characteristics of APA. The non-tumor portions of the microadenomas showed marked and sustained CYP11B2 mRNA expression under the suppressed renin-angiotensin system. We suggest that an increased number of microadenomas should be sampled, and the immunohistochemistry for steoridogenic enzymes should be investigated to clarify the etiology of microadenoma.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21801737     DOI: 10.1016/j.steroids.2011.07.004

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  4 in total

1.  Histopathological Classification of Cross-Sectional Image-Negative Hyperaldosteronism.

Authors:  Yuto Yamazaki; Yasuhiro Nakamura; Kei Omata; Kazue Ise; Yuta Tezuka; Yoshikiyo Ono; Ryo Morimoto; Yukinaga Nozawa; Celso E Gomez-Sanchez; Scott A Tomlins; William E Rainey; Sadayoshi Ito; Fumitoshi Satoh; Hironobu Sasano
Journal:  J Clin Endocrinol Metab       Date:  2017-04-01       Impact factor: 5.958

2.  Different expression of 11β-hydroxylase and aldosterone synthase between aldosterone-producing microadenomas and macroadenomas.

Authors:  Yoshikiyo Ono; Yasuhiro Nakamura; Takashi Maekawa; Saulo J A Felizola; Ryo Morimoto; Yoshitsugu Iwakura; Masataka Kudo; Kazumasa Seiji; Kei Takase; Yoichi Arai; Celso E Gomez-Sanchez; Sadayoshi Ito; Hironobu Sasano; Fumitoshi Satoh
Journal:  Hypertension       Date:  2014-05-19       Impact factor: 10.190

3.  Classification of microadenomas in patients with primary aldosteronism by steroid profiling.

Authors:  Yuhong Yang; Jacopo Burrello; Alessio Burrello; Graeme Eisenhofer; Mirko Peitzsch; Martina Tetti; Thomas Knösel; Felix Beuschlein; Jacques W M Lenders; Paolo Mulatero; Martin Reincke; Tracy Ann Williams
Journal:  J Steroid Biochem Mol Biol       Date:  2019-01-14       Impact factor: 4.292

4.  Validation of three novel clinical prediction tools for primary aldosteronism subtyping.

Authors:  Tomaž Kocjan; Gaj Vidmar; Peter Popović; Milenko Stanković
Journal:  Endocr Connect       Date:  2022-05-11       Impact factor: 3.221

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.